[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lumbar-degenerative-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lumbar-degenerative-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,77,113,137,165,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100639996","phase-2-the-effect-of-osteoporotic-medications-on-vertebral-bone-quality-score-100639996",false,"NCT07587775","The Effect of Osteoporotic Medications on Vertebral Bone Quality Score","Inclusion Criteria:\n\n* Diagnosis of Osteoporosis based on the following criteria:\n\n  * Fragility fracture (low trauma fracture similar to a fall from a standing position except for fracture to the skull, face, fingers, and toes)\n  * T score \\\u003C-2.5\n  * T-score -1 to -2.5 with a high FRAX or high TBS adjusted FRAX (with a 10-year probability of major osteoporotic fracture ≥20% or a 10-year probability of hip fracture ≥3%)\n* Fulfill criteria for treatment with anabolic therapy, as outlined in the American Association of Clinical Endocrinologist guidelines for the diagnosis and treatment of postmenopausal osteoporosis in women and Evidence-Based Guideline for the management of osteoporosis in men.\n* Lumbar Degenerative Disease as evidenced by a diagnosis of spondylosis, spondylolisthesis, degenerative disc disease with spinal stenosis, and degenerative scoliosis\n* Have or be willing to have a DEXA scan, lumbar MRI, and lumbar CT within 3 months of the start of Abaloparatide\n* If on thyroid hormone replacement, having been on it for at least 6 months\n\nExclusion Criteria:\n\n* Previous lumbar surgery\n* Past medical history of: sarcoma, including osteosarcoma, paget disease or other skeletal malignancies, unexplained elevations of alkaline phosphatase, prior external beam radiation, and pre-existing hypercalcemia\n* Diagnosis of secondary osteoporosis\n* Vitamin D deficit\n* History of prior treatment with TPTD and ABL","ALL","50 Years",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","The goal of this clinical trial is to determine the change in VBQ score, T score, TBS, and Hounsfield Units (HU) after 3-6 months of treatment with abaloparatide in osteoporotic patients who will undergo spinal fusion and decompression for lumbar degenerative disease. The main question\\[s\\] it aims to answer is:\n\nDoes abaloparatide improve bone density in these patients, as defined by VBQ score compared to traditional methods such as DEXA and Hounsfield Units Does abaloparatide reduce the incidence of postoperative mechanical complications, including adjacent segment disease, subsidence, and proximal junctional kyphosis (PKJ)?\n\nParticipants will undergo a presurgical assessments and trained in clinic on the subcutaneous application of abaloparatide. Prior to treatment, patients will have baseline assessments, including a lumbar MRI, DEXA scan, and lumbar CT. Post-surgically, participants will administer abaloparatide and return to clinic after 3-6 months for follow-up assessments including a new MRI, lumbar CT, and DEXA scan. Patients will be followed for up to 2 years postoperatively to identify complications such as adjacent segment disease, pseudarthrosis, failure of instrumentation, and PJK.",[25],"Lumbar Degenerative Disease",[27,28,25,29],"Osteoporosis","Spinal Fusion","Abaloparatide","NOT_YET_RECRUITING","2026-05-12",{"date":33,"type":34},"2026-05-14","ACTUAL",{"date":36,"type":19},"2026-06-01",{"date":38,"type":19},"2028-12-31",{"name":40,"class":41},"State University of New York at Buffalo","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":20,"phases":54,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100623395","pre-operative-risk-assessment-combined-with-targeted-intervention-in-the-chinese-elderly-with-spine-surgery-ii-100623395","NCT07396077","Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II","Multimodal Physiological Reserve Optimizing Prehabilitation Program (PHYSIO-Prehab) in the Chinese Elderly With Spine Surgery","PRACTICE-2","Inclusion Criteria:\n\n1. Aged ≥75 years at the time of screening\n2. Voluntarily sign the informed consent form\n3. Clinically diagnosed with degenerative lumbar spinal disorders with duration of symptoms \\>6 months\n4. Requiring elective lumbar fusion surgery (single-level or multi-level, open or minimally invasive approach)\n5. No severe cognitive impairment (Mini-Mental State Examination score \\> 9)\n6. Scheduled to undergo surgery within 6-8 weeks after screening (allowing completion of the 6-week prehabilitation program)\n\nExclusion Criteria:\n\n1. Scheduled to undergo other emergency surgery or day surgery\n2. Urgent medical conditions requiring priority management before spinal surgery\n3. With spinal disorders other than degenerative diseases (spinal fracture, tumor, metastasis, infection, ankylosing spondylitis, scoliosis with Cobb angle \\>40°)\n4. With contraindications to prehabilitation exercise (New York Heart Association Class IV heart failure, unstable angina, uncontrolled hypertension \\[systolic BP ≥180 mmHg or diastolic BP ≥110 mmHg despite medication\\])\n5. With severe functional disability for other disorders or long-term bedridden status unable to perform basic physical activities\n6. With allergy or intolerance to nutritional supplements used in the prehabilitation program\n7. Participating in another clinical trial involving prehabilitation, perioperative intervention, or spinal surgery within 3 months before screening","75 Years",{"count":53,"type":19},248,[55],"NA","This multicenter, parallel-group, assessor-blinded randomized controlled trial will enroll 248 adults aged ≥75 years with degenerative lumbar spinal diseases scheduled for elective lumbar fusion surgery, and they will be randomized 1:1 into the intervention and usual care groups. The intervention group will receive a 6-week PHYSIO-Prehab multimodal prehabilitation program, including multicomponent exercise, nutritional intervention, comorbidity optimization, and cognitive prehabilitation with brain protection strategies. The control group will receive standard health education provided via a manual, and both groups will receive consistent perioperative Enhanced Recovery After Surgery care. The primary outcome will be the change in Barthel Index (a tool for assessing independence in activities of daily living) from baseline to 30 days postoperatively; secondary outcomes will include pain scores, disability, patient satisfaction, and the 30-day postoperative Comprehensive Complication Index. The trial will initiate recruitment in April 2026 and conclude in December 2027, aiming to evaluate the feasibility and efficacy of PHYSIO-Prehab and provide high-quality evidence for patient-centered perioperative care pathways in this population.",[58,25,59,60,61],"Spine Degeneration","Frail Elderly","Enhanced Recovery After Surgery (ERAS) Protocol","Prehabilitation",[61,63,64,65],"ERAS","lumbar fusion","ADL","RECRUITING","2026-04-26",{"date":69,"type":34},"2026-04-28",{"date":71,"type":34},"2026-04-15",{"date":73,"type":19},"2027-12-30",{"name":75,"class":41},"Xuanwu Hospital, Beijing",4,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":20,"phases":88,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":42},"100602735","comparison-of-clinical-outcomes-complications-rate-and-treatment-costs-of-mini-tlif-and-midlif-in-the-treatment-of-discogenic-low-back-pain-100602735","NCT07127380","Comparison of Clinical Outcomes, Complications Rate and Treatment Costs of Mini-TLIF and MIDLIF in the Treatment of Discogenic Low Back Pain","MID-MIS Trail Protocol - Comparison of Clinical Outcomes, Complications Rate and Treatment Costs of Mini-TLIF and MIDLIF in the Treatment of Discogenic Low Back Pain","MID-MIS","Inclusion Criteria:\n\n* Discogenic lower lumbar-sacral pain lasting longer than one year\n* Failure of conservative treatment, including rehabilitation and pain management\n* Lumbar discopathy qualified for interbody fusion and pedicle screw stabilization\n* Informed consent of the patient for the study and proposed treatment\n\nExclusion Criteria:\n\n* Contraindications to surgery under general anesthesia\n* Age \\\u003C 18 years\n* Pregnancy, breastfeeding\n* Lack of informed consent to participate in the study\n* Lumbar-sac discopathy requiring surgical treatment at more than two levels\n* Spinal deformities: adult idiopathic scoliosis, degenerative scoliosis, deformity due to spinal malignancy, inflammatory spinal disease, post-traumatic, or associated with congenital anomalies\n* Lower lumbar-sacral pain syndrome, which, in the investigator's opinion, has an etiology other than degenerative spine disease (e.g., cancer-related pain, ankylosing spondylitis)\n* Spinal oncology disease\n* True and degenerative spondylolisthesis\n* Contraindications to performing MRI of the lumbar-sacral spine","18 Years",{"count":87,"type":19},100,[55],"Background\n\nDegenerative disc disease (DDD) is the leading cause of lower back pain and disability, which prevalence increasing with age. When conservative treatment fails, surgical methods of spinal fusion are employed. Minimally invasive techniques, including minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) and midline lumbar interbody fusion (MIDLIF), have well-documented advantages over traditional open transforaminal interbody fusion (open-TLIF). However, data comparing these two minimally invasive methods in treating DDD are minimal and sometimes contradictory. I am running a few minutes late; my previous meeting is running over.\n\nMethods This is a prospective, randomized, partially blinded, two-arm trial aiming to compare the outcomes, complications, and treatment costs of MIS-TLIF and MIDLIF in patients with discogenic low back pain. A total of 100 adult patients with lumbosacral spine pain and radicular symptoms, unresponsive to conservative treatment for over one year, will be enrolled. Patients will be randomized (1:1) into two arms: MIS-TLIF (control, n=50) and MIDLIF (intervention, n=50), with a 12-month follow-up. Inclusion criteria include age ≥18 years and discopathy at one or two levels requiring interbody stabilization. Exclusion criteria include multilevel pathology, spinal deformities, and pain causes other than degenerative disease. Primary endpoints assess pain (VAS, NRS scales), disability (COMI, ODI questionnaires), and quality of life (EQ-5D-5L questionnaire) at 1, 3, 6, and 12 months post-surgery. Secondary endpoints include complication rates (nerve root damage, infections), costs (hospitalization, implants), length of hospital stay, procedure duration, blood loss, morphometric parameters (intervertebral space height), and adjacent segment disease based on imaging studies (MRI, CT, X-ray). Data analysis uses parametric\u002Fnon-parametric tests (e.g., t-test, Mann-Whitney) in the R software. The trial adheres to the Helsinki Declaration, with ethics approval (no. 112\u002F2024).\n\nDiscussion Data on the comparison of MIDLIF and MIS-TLIF in treating DDD are minimal and inconsistent. Some reports have advantaged MIDLIF in shorter operative time, decreased intraoperative blood loss, and reduced hospital stays, while others favor MIS-TLIF. This trial addresses these gaps by providing high-quality evidence on clinical superiority, cost-effectiveness, and long-term outcomes compering MIDLIF and MIS-TLIF. There is a high need for a high-quality, prospective study to examine this problem.",[91,25,92,93],"Lower Back Pain Chronic","Lumbar Disc Degeneration","Degenerative Disc Disease(DDD)",[95,96,92,97,98,99,100,101,102,103,104],"Degenerative Disc Disease","Lower Back Pain","Discogenic Pain","MIS-TLIF","MIDLIF","mini-TLIF","Minimally Invasive Transforaminal Lumbar Interbody Fusion","Midline Lumbar Interbody Fusion","Spinal stabilization","Spinal fusion","2026-04-14",{"date":71,"type":34},{"date":108,"type":34},"2025-01-19",{"date":110,"type":19},"2028-01-31",{"name":112,"class":41},"Copernicus Memorial Hospital",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":98,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":15,"minAge":120,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":20,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":42},"100573671","comparison-of-endoscopic-lumbar-decompression-and-minimally-invasive-transforaminal-lumbar-interbody-fusionmis-tlif-for-degenerative-lumbar-spondylolisthesis-100573671","NCT06749314","Comparison of Endoscopic Lumbar Decompression and Minimally Invasive Transforaminal Lumbar Interbody Fusion(MIS-TLIF) for Degenerative Lumbar Spondylolisthesis","Comparison of Endoscopic Lumbar Decompression and Minimal Invasive Surgery Transforaminal Lumbar Interbody Fusion (MIS-TLIF) for Degenerative Lumbar Spondylolisthesis: A Randomized Controlled Study","Inclusion Criteria:\n\n* Single level lumbar degenerative spondylolisthesis (Meyerding Grading Grade I or II).\n* Failed conservative treatment for at least 3 months.\n* No instability evidence of levels of lesion (Consideration from translation more than 5 mm or angulation change more than 10 degree in flexion and extension L-S plain films ).\n* Able to follow up for at least 12 months.\n* Patient who vorantarily agree to participate in research.\n\nExclusion Criteria:\n\n* Patients with severe foraminal stenosis diagnosed by MRI.\n* Patients who have previously undergone lumbar spine surgery (revision surgery).\n* Patients with other abnormalities in the lumbar spine, such as infection, tumors, or fractures.\n* Patients who cannot undergo surgery due to underlying conditions or who cannot maintain the prone position for extended periods.","40 Years",{"count":122,"type":19},66,[55],"Comparing the functional and radiographic outcomes in surgical treatment in failed conservative treatment, single-level low grade degenerative lumbar spondylolisthesis between Minimal Invasive Surgery Transforaminal Lumbar Interbody Fusion, which is conventional treatment recently, and Endoscopic Lumbar Decompression, which is minimal invasive in symptomatic treatment.",[126,25,127],"Degenerative Lumbar Spondylolisthesis","Lumbar Spinal Stenosis","2025-04-21",{"date":130,"type":34},"2025-04-22",{"date":132,"type":19},"2025-05-01",{"date":134,"type":19},"2026-05-31",{"name":136,"class":41},"Queen Savang Vadhana Memorial Hospital, Thailand",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":15,"minAge":85,"maxAge":4,"enrollmentInfo":144,"targetDuration":146,"studyType":147,"phases":4,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":42},"100588365","conduit-anterior-lumbar-interbody-fusion-alif-cage-system-in-lumbar-degenerative-disease-100588365","NCT06940453","CONDUIT™ Anterior Lumbar Interbody Fusion (ALIF) Cage System in Lumbar Degenerative Disease","Clinical\u002FRadiological Outcomes Associated With CONDUIT™ Anterior Lumbar Interbody Fusion (ALIF) Cage System With Supplemental Fixation for Treatment of Lumbar Degenerative Disc Disease at One or Two Contiguous Spinal Levels From L2-S1","Inclusion Criteria:\n\n* Aged ≥ 18 years old\n* Consenting patients undergoing anterior lumbar interbody fusion (ALIF) procedure whom the Conduit cage system is appropriate will be included in this study.\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Non-surgical candidates, patients with contraindications to surgery (e.g. medical comorbidities, known infection, pregnancy etc.),\n* Patients with established osteoporosis\n* Long-term, systemic steroid use\n* Systemic diseases (e.g. rheumatoid arthritis, AIDS, HIV, etc.),\n* Patients unwilling or unable to give informed consent, or patients unwilling or unable to complete Health-related quality of (HRQOL) outcome life measures at the specified study time points pre- and post-operatively.\n* Subjects who have a history of drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements.",{"count":145,"type":19},35,"24 Months","OBSERVATIONAL","This will be a prospective, multi-centre study at a National Tertiary Referral Centre for spinal trauma and spinal cord injuries, serving a catchment area of 5 million people. This study will follow patients undergoing anterior lumbar interbody fusion (ALIF) procedure. This trial seeks to evaluate the performance of this CE-marked device, and to assess outcomes in frail and non-frail patient cohorts. The CONDUIT™ ALIF Cage System are intervertebral body fusion devices intended for use for anterior lumbar interbody fusion in skeletally mature patients. The devices are 3D printed cellular titanium implants that feature 80% porous macro-, micro- and nanostructures, are designed to mimic cortical and cancellous bone, and facilitate fusion. This pilot study hypothesizes that the use of CONDUIT ALIF Cage system to treat lumbar degenerative disc disease will achieve results comparable to historical cases using SYNFIX Systems.",[25],[151,152,153,154,155],"INTERBODY FUSION","SPINE SURGERY","LUMBAR DEGENERATION","SPINAL FUSION","SPINAL FIXATION","2025-04-15",{"date":158,"type":34},"2025-04-23",{"date":160,"type":34},"2024-06-28",{"date":162,"type":19},"2027-12-31",{"name":164,"class":41},"University College Dublin",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":15,"minAge":85,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":20,"phases":175,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":4},"100566659","phase-4-erector-spinae-plan-block-espb-with-dexmedetomidine-and-dexamethasone-in-lumbar-spine-fusion-100566659","NCT06658054","Erector Spinae Plan Block (ESPB) with Dexmedetomidine and Dexamethasone in Lumbar Spine Fusion","Analgesic Efficacy of Erector Spinae Plane Block with Dexmedetomidine and Dexamethasone As Adjuvants in Single to Three-Level Lumbar Spine Fusion","ESPB","Inclusion Criteria:\n\n* Medically optimized patients undergoing 1-3 level lumbar fusion surgery for treatment of degenerative lumbar spinal pathologies\n* Aged 18 years or older\n* English-speaking patients\n\nExclusion Criteria:\n\n* Patients with surgical indications for infection, malignancy, or trauma\n* women who are pregnancy or breastfeeding\n* Patients with respiratory compromise\n* Patients who are smokers\n* Patients with allergies to local anesthetics, and\u002For opioid medications",{"count":174,"type":19},46,[176],"PHASE4","This study wants to understand if using a pre-operative anesthetic injection could contribute to better pain relief after the surgery. This injection is referred to as an erector spinae plane block (ESPB, or \"Block\" for short). In the past, blocks have been commonly used to alleviate different types of pain, including pain following lumbar spine surgery, but our investigators are curious to study if adding two additional commonly used drugs could improve pain relief following surgery when used together. This possibility for improvement in pain management is important for our doctors to study because they want to find ways to reduce the amount of pain medication required after surgery.\n\nWe try to assess if one treatment is better than the other by looking into the amount of pain medication used immediately after the surgery (up to five times within the first 2 days; this is usually done by reviewing progress notes) and by asking patients if they can share with us their pain experienced at different times during their stay at the hospital and at 2-weeks after their procedure.",[25],[180,171,181,182,183,184,185,186,187,188,189,190,191,192],"analgesia","erector spinae plane block","dexmedetomidine","dexamethasone","bupivacaine","randomized","blinded","postoperative","opioid","PONV","nausea","vomitting","fusion","2024-10-22",{"date":195,"type":34},"2024-10-26",{"date":197,"type":19},"2024-11",{"date":199,"type":19},"2026-11",{"name":201,"class":41},"University of Southern California",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":15,"minAge":85,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":20,"phases":211,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":42},"100566043","study-on-topping-off-technique-for-treating-ldd-100566043","NCT06650046","Study on Topping-off Technique for Treating LDD","Study on Topping-off Technique for Treating Lumbar Degenerative Diseases","Inclusion Criteria:\n\n* The patient's clinical manifestations, physical examination, and imaging data all support the diagnosis of degenerative lumbar spondylosis.\n* Those who have undergone strict and formal conservative treatment for at least 3 months before surgery and have no significant improvement in symptoms.\n* Preoperative imaging examination showed L4-5 and L5-S1 responsible segment protrusion or protrusion leading to segment stenosis.\n* Surgeries are performed by the same chief surgeon.\n\nExclusion Criteria:\n\n* Lumbar instability, lumbar spondylolisthesis above grade II.\n* Patients with severe osteoporosis, tuberculosis, or tumors.\n* Systemic diseases that affect surgical treatment and medication, such as heart disease, liver disease, and kidney disease.\n* Patients with mental illness, poor compliance, and inability to cooperate in completing follow-up.","85 Years",{"count":87,"type":19},[55],"Lumbar degenerative disease is a common disease among middle-aged and elderly people as well as those who sit for a long time, mainly manifested as symptoms such as lower back pain, stiffness, and numbness in the lower limbs. Traditional surgical treatments such as lumbar fusion can alleviate symptoms, but may lead to complications such as adjacent segment degeneration. Therefore, exploring safer and more effective treatment methods is of great significance. Topping off technique, as a new treatment method, combines the advantages of interbody fusion and dynamic fixation, aiming to reduce the pressure on the intervertebral disc at the surgical site, promote the repair of diseased intervertebral discs, while preserving partial mobility of the lumbar spine.The aim of this study is to evaluate the clinical efficacy and imaging changes of Topping off technique in the treatment of lumbar degenerative diseases. The Topping off technique combines posterior lumbar interbody fusion (PLIF) and Wallis interspinous dynamic fixation device implantation. Through prospective clinical trials, its therapeutic effect on patients with continuous double segment lumbar degenerative diseases was observed. The study included patients who underwent surgery for degenerative lumbar diseases in L4-5 and L5-S1, who were treated with two-stage fusion surgery and Topping off technique, respectively. Follow up was conducted before and after surgery, with an average follow-up time of 24 months. Evaluate preoperative and postoperative efficacy using Oswestry Disability Index (ODI), Pain Visual Analog Scale (VAS), and Japanese Orthopaedic Association (JOA) lumbar spine function score, and calculate recovery rate. At the same time, X-ray and MRI images were used to detect the overall range of motion (L2\\~S1ROM) of the lumbar spine, the range of motion (ROM) of the Wallis device inserted segments, the intervertebral disc height index (DHI), and the relative signal intensity of the nucleus pulposus (RSI) of the intervertebral disc.",[25],[215],"Topping-off technique","2024-10-17",{"date":218,"type":34},"2024-10-21",{"date":220,"type":34},"2024-10-18",{"date":222,"type":19},"2029-12-31",{"name":224,"class":41},"Qianfoshan Hospital"]